The aim: Research of blood lipid spectrum, level of anti-inflammatory cytokines and C-reactive protein of coronary heart disease patients. Materials and methods: There was examined 61 patients with unstable angina, who had been on hospital care in the cardiology department of the Lviv National Emergency Hospital. Their average age was 68.3 ± 1.9 years. The control group included 20 generally healthy persons. There was estimated blood lipid spectrum, C-reactive protein, fibrinogen and proinflammatory cytokine of patients. Results: There was determined considerable increase total cholesterol, low density lipoprotein cholesterol, very low density lipoprotein cholesterol, triglycerides and coefficient of atherogenicity. High level of C-reactive protein and pro-inflammatory cytokines were detected in patients with unstable angina. Conclusions: In patients with unstable angina was revealed a significant increase of proinflammatory cytokines levels in the blood serum: interleukin-1β, interleukin-6, interleukin-17, TNF-α and C-reactive protein, fibrinogen, which indicates activation of the inflammatory process. In patients with unstable angina was detected a significant disorder of blood lipid spectrum. For its correction should be recommended diet and hypolipidemic agents.

To accomplish the synthesis and screening of anticancer and antimicrobial activities of 1-[2-amino-4-methylthiazol-5-yl]-3-arylpropenones 2-10. Methods. The in vitro anticancer activity of compounds 4, 6, 8-10 has been established by DTP(Developmental Therapeutics Program) of the National Cancer Institute. The antibacterial and antifungal activities of synthesized thiazole-based derivatives were evaluated in vitro with the agar diffusion and broth microdilution methods to wards Gram-positive, Gram-negative bacteria and yeasts. For the synthesized compounds, the in silico drug-likeness screening using SwissADME online server is reported. Results. The novel 1-[2-amino-4-methylthiazol-5-yl]-3-arylpropenones were synthesized from 1-[2-amino-4-methylthiazol-5-yl]ethanones and various aromatic aldehydes in the Claisen-Schmidt condensation. The synthesized compound 9 was moderately active against the leukemia CCRF-CEM and HL-60(TB), renal cancer UO-31 and breast cancer MCF7 cell lines. The antimicrobial screening led to identification of the active compound 10 against Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans. Conclusions. The results obtained herein provide a platform for structure-based optimization of these newly identified thiazole-based compounds for the anticancer and antibacterial drug design.

Hepatoprotectors – drugs that form the basis of pathogenetic treatment of various liver diseases. They help restore impaired hepatocyte function, increase the resistance of liver cells to the effects of pathological factors, enhance the detoxification function of hepatocytes, have antioxidant properties. There is no generally accepted classification of hepatoprotectors today, they are divided into several groups depending on the origin: plant, animal, synthetic origin, products containing essential phospholipids, amino acids, vitamins, and other groups. One of the well-known hepatoprotectors of plant origin is glycyrrhizin – the main active ingredient of licorice root. Licorice root (Glycyrrhiza glabra) is a drug used in medicine since ancient times, as evidenced by historical data from China, Japan, India, Greece, and Europe. Licorice root is widely used today in medicine and the food industry. Glycyrrhizin – potassium and calcium salt of glycyrrhizinic acid, has a wide range of properties. It is used mainly for the treatment of chronic liver disease. In non-alcoholic fatty liver disease, the use of glycyrrhizin helps reduce steatosis, inflammation in the liver has an antifibrotic effect. Studies on the use of glycyrrhizinic acid in hepatocellular carcinoma are actively conducted, as its antitumor properties are known. It is included in the treatment of chronic viral hepatitis. In vitro studies have shown the antiviral activity of glycyrrhizin against HIV-1, SARS-associated virus, respiratory syncytial virus, arboviruses, and its potential for coronavirus control is being discussed. Possibilities of application of glycyrrhizin and cardiovascular diseases are studied. In this article, we present a review of current literature data on glycerol, its properties, and applications in liver disease, other diseases, and our own clinical observations.

No abstract

Львівський національний медичний університет імені данила Галицького Мета дослідження: визначення ефективності застосування гепатопротектора гепаризину у хворих на нестабільну стенокардію (НС) у поєднанні з неалкогольною жировою хворобою печінки (НАЖХП). Матеріали та методи. Обстежено 42 хворих на НС, серед яких 24 пацієнтів з НС у поєднанні з НАЖХП, 18 хворих на НС і 20 осіб контрольної групи. Пацієнти із поєднаною патологією отримували гепатопротектор. У хворих оцінювали показники ліпідного спектра крові та функціональний стан печінки. Результати. Під час оцінювання ліпідного спектра крові у хворих на НС виявляли дисліпідемію. Після проведеного лікування в обох групах спостерігалося покращення показників ліпідограми. У хворих на НС із супутньою НАЖХП відзначали деяке підвищення рівня трансаміназ та зниження їхнього рівня після проведеного лікування. Заключення. Застосування гепаризину у хворих на нестабільну стенокардію у поєднанні з неалкогольною жировою хворобою печінки позитивно впливало на функціональний стан печінки та сприяло зниженню рівня трансаміназ після проведеного лікування. Суттєвого впливу гепаризину на покращання ліпідного спектра крові не спостерігали. Ключові слова: нестабільна стенокардія, неалкогольна жирова хвороба печінки, ліпідний спектр крові, трансамінази.

The article presents current data on markers of endothelial function and inflammation, and their importance in ischemic heart disease.